These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 27537699)

  • 1. Improved Quantification of the Beta Cell Mass after Pancreas Visualization with
    van der Kroon I; Joosten L; Nock BA; Maina T; Boerman OC; Brom M; Gotthardt M
    Mol Pharm; 2016 Oct; 13(10):3478-3483. PubMed ID: 27537699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measuring the Pancreatic β Cell Mass in Vivo with Exendin SPECT during Hyperglycemia and Severe Insulitis.
    Joosten L; Brom M; Peeters H; Bos D; Himpe E; Bouwens L; Boerman O; Gotthardt M
    Mol Pharm; 2019 Sep; 16(9):4024-4030. PubMed ID: 31345042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A standardized method for in vivo mouse pancreas imaging and semiquantitative β cell mass measurement by dual isotope SPECT.
    Mathijs I; Xavier C; Peleman C; Caveliers V; Brom M; Gotthardt M; Herrera PL; Lahoutte T; Bouwens L
    Mol Imaging Biol; 2015 Feb; 17(1):58-66. PubMed ID: 25070262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishment of a method for in-vivo SPECT/CT imaging analysis of
    Hamamatsu K; Fujimoto H; Fujita N; Murakami T; Kimura H; Saji H; Inagaki N
    Nucl Med Biol; 2018; 64-65():22-27. PubMed ID: 30015092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-invasive quantification of the beta cell mass by SPECT with ¹¹¹In-labelled exendin.
    Brom M; Woliner-van der Weg W; Joosten L; Frielink C; Bouckenooghe T; Rijken P; Andralojc K; Göke BJ; de Jong M; Eizirik DL; Béhé M; Lahoutte T; Oyen WJ; Tack CJ; Janssen M; Boerman OC; Gotthardt M
    Diabetologia; 2014 May; 57(5):950-9. PubMed ID: 24488022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological evaluation of an
    Kimura H; Fujita N; Kanbe K; Matsuda H; Watanabe H; Arimitsu K; Fujimoto H; Hamamatsu K; Yagi Y; Ono M; Inagaki N; Saji H
    Bioorg Med Chem; 2017 Oct; 25(20):5772-5778. PubMed ID: 28927802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noninvasive Imaging of Islet Transplants with 111In-Exendin-3 SPECT/CT.
    van der Kroon I; Andralojc K; Willekens SM; Bos D; Joosten L; Boerman OC; Brom M; Gotthardt M
    J Nucl Med; 2016 May; 57(5):799-804. PubMed ID: 26795287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced Specific Activity by Multichelation of Exendin-3 Leads To Improved Image Quality and In Vivo Beta Cell Imaging.
    Joosten L; Brom M; Peeters H; Heskamp S; Béhé M; Boerman O; Gotthardt M
    Mol Pharm; 2018 Feb; 15(2):486-494. PubMed ID: 29226686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT.
    Wild D; Wicki A; Mansi R; Béhé M; Keil B; Bernhardt P; Christofori G; Ell PJ; Mäcke HR
    J Nucl Med; 2010 Jul; 51(7):1059-67. PubMed ID: 20595511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of radiolabelled exendin for beta cell imaging by ex vivo autoradiography and immunohistochemistry of human pancreas.
    Jansen TJP; Tokgöz S; Buitinga M; van Lith SAM; Joosten L; Frielink C; Smeets EMM; Stommel MWJ; van der Kolk MB; de Galan BE; Brom M; Boss M; Gotthardt M
    EJNMMI Res; 2024 Oct; 14(1):96. PubMed ID: 39405026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Species differences of bombesin analog interactions with GRP-R define the choice of animal models in the development of GRP-R-targeting drugs.
    Maina T; Nock BA; Zhang H; Nikolopoulou A; Waser B; Reubi JC; Maecke HR
    J Nucl Med; 2005 May; 46(5):823-30. PubMed ID: 15872357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo imaging of the glucagonlike peptide 1 receptor in the pancreas with 68Ga-labeled DO3A-exendin-4.
    Selvaraju RK; Velikyan I; Johansson L; Wu Z; Todorov I; Shively J; Kandeel F; Korsgren O; Eriksson O
    J Nucl Med; 2013 Aug; 54(8):1458-63. PubMed ID: 23761918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strain Differences Determine the Suitability of Animal Models for Noninvasive In Vivo Beta Cell Mass Determination with Radiolabeled Exendin.
    Willekens SM; Joosten L; Boerman OC; Balhuizen A; Eizirik DL; Gotthardt M; Brom M
    Mol Imaging Biol; 2016 Oct; 18(5):705-14. PubMed ID: 26886298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of the preservation effect of canagliflozin on pancreatic beta cell mass using SPECT/CT imaging with
    Hamamatsu K; Fujimoto H; Fujita N; Murakami T; Shiotani M; Toyoda K; Inagaki N
    Sci Rep; 2019 Dec; 9(1):18338. PubMed ID: 31797889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SPECT-OPT multimodal imaging enables accurate evaluation of radiotracers for β-cell mass assessments.
    Eter WA; Parween S; Joosten L; Frielink C; Eriksson M; Brom M; Ahlgren U; Gotthardt M
    Sci Rep; 2016 Apr; 6():24576. PubMed ID: 27080529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 64Cu- and 68Ga-labelled [Nle(14),Lys(40)(Ahx-NODAGA)NH2]-exendin-4 for pancreatic beta cell imaging in rats.
    Mikkola K; Yim CB; Fagerholm V; Ishizu T; Elomaa VV; Rajander J; Jurttila J; Saanijoki T; Tolvanen T; Tirri M; Gourni E; Béhé M; Gotthardt M; Reubi JC; Mäcke H; Roivainen A; Solin O; Nuutila P
    Mol Imaging Biol; 2014 Apr; 16(2):255-63. PubMed ID: 24101374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (111)In-exendin uptake in the pancreas correlates with the β-cell mass and not with the α-cell mass.
    Brom M; Joosten L; Frielink C; Boerman O; Gotthardt M
    Diabetes; 2015 Apr; 64(4):1324-8. PubMed ID: 25409700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of
    Brom M; Joosten L; Frielink C; Peeters H; Bos D; van Zanten M; Boerman O; Gotthardt M
    Diabetes; 2018 Oct; 67(10):2012-2018. PubMed ID: 30045920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-invasive in vivo determination of viable islet graft volume by
    Eter WA; Van der Kroon I; Andralojc K; Buitinga M; Willekens SMA; Frielink C; Bos D; Joosten L; Boerman OC; Brom M; Gotthardt M
    Sci Rep; 2017 Aug; 7(1):7232. PubMed ID: 28775287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bombesin receptor antagonists may be preferable to agonists for tumor targeting.
    Cescato R; Maina T; Nock B; Nikolopoulou A; Charalambidis D; Piccand V; Reubi JC
    J Nucl Med; 2008 Feb; 49(2):318-26. PubMed ID: 18199616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.